Avid Bioservices Inc (CDMO)

[newbieee]

David Carbone mentioned in the Columbus Dispatch today. Using a $3 million Pelotonia grant researcheers at OSU wil conduct a statewide research study
that will genetically test
more than 2,000 advanced
lung-cancer patients in an
effort to treat their illness
with targeted therapy.
The three-year Beating
Lung Cancer in Ohio initiative,
to begin in March,
will recruit patients newly
diagnosed with Stage 4 nonsmall-
cell lung cancer. They
will receive free testing for
300 genes, while also being
tested for a PD-L1 marker
used to help select certain
immunotherapy treatments.It often is
diagnosed in a metastatic,
or fourth, advanced state,
said Dr. David Carbone, one
of the lead researchers on
the study and director of the
Thoracic Cancer Center at
The James.
“Getting patients on the
right treatment — the first
time — is absolutely critical,”
Carbone said in a statement.
“We know advanced
genomic testing can help
us identify the patients
most likely to benefit from
a targeted therapy, which
is oftentimes a pill and
well-tolerated, vs. traditional
chemotherapies not
specifically targeted to that
patient’s genetic mutations.